BioCentury
ARTICLE | Clinical News

Curacyte ends Phase III trial of shock candidate

August 30, 2011 12:10 AM UTC

Curacyte AG (Munich, Germany) terminated the European Phase III PHOENIX trial of distributive shock candidate hemoximer (pyridoxalated hemoglobin polyoxyethylene, or PHP) after an interim analysis showed a higher number of deaths in the treatment arm compared to the placebo arm. An independent DMB concluded that the trial will not meet the primary endpoint of all-cause mortality at 28 days. The trial, which has enrolled 377 of a planned 454 patients, was evaluating a continuous IV infusion of hemoximer plus vasopressor therapy in patients with catecholamine-resistant distributive shock for a maximum of 150 hours. Hemoximer is a nitric oxide (NO) scavenger. ...